MannKind el­e­vates Cas­tan­ga to CEO; 23andMe re­cruits 5,000 women for study in 9 days

→  Fi­nan­cial­ly-trou­bled MannKind el­e­vat­ed Michael Cas­tan­ga from chief com­mer­cial of­fi­cer to CEO. Matthew Pf­ef­fer, the out­go­ing chief ex­ec­u­tive, will con­tin­ue ad­vis­ing the com­pa­ny un­til the end of Ju­ly. The com­pa­ny strug­gled its way through the clin­ic to end up with an in­haled in­sulin that di­a­bet­ics have shunned.

→  Ei­sai and Charles Riv­er Lab­o­ra­to­ry have ex­tend­ed their pre­clin­i­cal dis­cov­ery pact for an­oth­er year. The two com­pa­nies have been fo­cus­ing on nov­el drugs for trop­i­cal and neu­ro­log­i­cal dis­eases. Re­searchers will be­gin work­ing with the Med­i­cines for Malar­ia Ven­ture, which is look­ing for new com­pounds to treat drug-re­sis­tant malar­ia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.